R-Pharm US Acquires Breast Cancer Drug Ixempra From Bristol-Myers Squibb

(RTTNews) - R-Pharm US announced that it acquired breast cancer drug Ixempra (ixabepilone) from Bristol-Myers Squibb Co. (BMY). Financial terms were not disclosed.

Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

Ixempra received marketing approval from the U.S. Food and Drug Administration in 2007 and in 18 other markets globally.

With the acquisition, R-Pharm US has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement.